Roth Capital Initiates Coverage On Bioage Labs with Buy Rating, Announces Price Target of $36
Benzinga Newsdesk 5 months ago
NewsPrice TargetInitiationAnalyst Ratings
Roth Capital analyst Adam Walsh initiates coverage on Bioage Labs (NASDAQ:BIOA) with a Buy rating and announces Price Target of $36.
Roth Capital analyst Adam Walsh initiates coverage on Bioage Labs (NASDAQ:BIOA) with a Buy rating and announces Price Target of $36.